Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Purification of Capsular Polysaccharide Produced by Streptococcus pneumoniae Serotype 19A

  • Jung, Seung-Jin (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University) ;
  • Seo, Eun-Seong (School of Biological Sciences and Technology, Chonnam National University) ;
  • Yun, Sang-Il (School of Biological Sciences and Technology, Chonnam National University) ;
  • Minh, Bui Nguyet (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University) ;
  • Jin, Sheng-De (School of Biological Sciences and Technology, Chonnam National University) ;
  • Ryu, Hwa-Ja (School of Biological Sciences and Technology, Chonnam National University) ;
  • Kim, Do-Man (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University)
  • Received : 2010.10.21
  • Accepted : 2011.05.07
  • Published : 2011.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Streptococcus pneumoniae is a major cause of invasive infection in young infants and older adults. There are currently 90 capsular serotypes identified and 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) are responsible for about 90% of invasive disease. Among the more than 90 different S. pneumoniae serotypes, serotype 19A is globally very prevalent. A simplified purification procedure including adjustment of cell lysate pH to 4.5, fractionation with 50. 80% ethanol, and dialysis rendered capsular polysaccharide (CPS) in a yield of $31.32{\pm}3.11$ mg from 1 l culture (75% recovery after lyses). The product contained only 69.6 ${\mu}g$ of protein (99.78% purity) and 0.8mg (sum of the precipitants from 50~60%, 60~70%, and 70~80%) of nucleic acid (97.45% purity). The purified CPS was conjugated with bovine serum albumin; the product size ranged from 100 to 180 kDa.

Keywords

References

  1. Alonso de Velasco, E., A. F. Verheul, G. H. Veeneman, L. J. Gomes, J. H. van Boom, J. Verhoef, and H. Snippe. 1993. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine 11: 1429-1436. https://doi.org/10.1016/0264-410X(93)90172-T
  2. Arnold, F. 1998. Alcohol-free pneumococcal polysaccharide purification process. US Patent 5714354.
  3. Avery, O. T. and R. Dubos. 1931. The protective action of a specific enzyme against type Iii pneumococcus infection in mice. J. Exp. Med. 54: 73-89. https://doi.org/10.1084/jem.54.1.73
  4. Bednar, B. and J. P. Hennessey. 1993. Molecular size analysis of capsular polysaccharide preparations from Streptococcus pneumoniae. Carbohydr. Res. 243: 115-130. https://doi.org/10.1016/0008-6215(93)84085-K
  5. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254. https://doi.org/10.1016/0003-2697(76)90527-3
  6. Brian, B., T. Lee, J. A. Lotvin, M. E. Ruppen, and P. F. Charbonneau. 2006. Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation. US Patent 0228381.
  7. Bruyn, G. A. and R. van Furth. 1991. Pneumococcal polysaccharide vaccines: Indications, efficacy and recommendations. Eur. J. Clin. Microbiol. Infect. Dis. 10: 897-910. https://doi.org/10.1007/BF02005442
  8. Cano, F. J. S. V., J. S. C. O. Kuo, and M. V. R. V. Querry. 1980. Purification of pneumococcal capsular polysaccharides. US Patent 4242501.
  9. Choi, E. H., S. H. Kim, B. W. Eun, S. J. Kim, N. H. Kim, J. Lee, and H. J. Lee. 2008. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14: 275-281. https://doi.org/10.3201/eid1402.070807
  10. Dagan, R., M. Isaachson, R. Lang, J. Karpuch, C. Block, and J. Amir. 1994. Epidemiology of pediatric meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in Israel: A 3-year nationwide prospective study. J. Infect. Dis. 169: 912-916. https://doi.org/10.1093/infdis/169.4.912
  11. Ghebregzabher, M., S. Rufini, B. Monaldi, and M. Lato. 1976. Thin-layer chromatography of carbohydrates. J. Chromatogr. 127: 133-162. https://doi.org/10.1016/S0021-9673(00)80168-5
  12. Katzenellenbogen, E. and H. J. Jennings. 1983. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A. Carbohydr. Res. 124: 235-245. https://doi.org/10.1016/0008-6215(83)88459-6
  13. Musher, D. M. 1992. Infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14: 801-807. https://doi.org/10.1093/clinids/14.4.801
  14. Myers, C. and A. Gervaix. 2007. Streptococcus pneumoniae bacteraemia in children. Int. J. Antimicrob. Agents 30S: S24- S28.
  15. Pelton, S. I., H. Huot, J. A. Finkelstein, C. J. Bishop, K. K. Hsu, and J. Kellenberg. 2007. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26: 468-472. https://doi.org/10.1097/INF.0b013e31803df9ca
  16. Skov-Sorensen, U. B., J. Blom, A. Birch-Andersen, and J. Henrichsen. 1988. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect. Immun. 56: 1890-1896.
  17. World Health Organisation. 2000. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Tech. Rep. Ser. 897: 27-56.
  18. World Health Organization (2005). Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser. 927: 64-98.
  19. World Health Organization. 2004. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Tech. Rep. Ser. 924: 102-128.
  20. Yuan, Y. T., M. G. Ruppen, W. M. Sun, L. S. Chu, J. U. N. Simpson, J. C. O. H. Patch, J. K. V. C. Moran, and P. N. C. Fink. 2008. Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharide. US Patent WO/2008/118752.

Cited by

  1. DEVELOPMENT OF A NEW PROCESS FOR PURIFICATION OF CAPSULAR POLYSACCHARIDE FROM Streptococcus pneumoniae SEROTYPE 14 vol.33, pp.3, 2011, https://doi.org/10.1590/0104-6632.20160333s20150140
  2. Purification of Capsular Polysaccharides of Streptococcus pneumoniae : Traditional and New Methods vol.6, pp.None, 2011, https://doi.org/10.3389/fbioe.2018.00145
  3. Generation of a Human Monoclonal Antibody to Cross-Reactive Material 197 (CRM197) and Development of a Sandwich ELISA for CRM197 Conjugate Vaccines vol.28, pp.12, 2011, https://doi.org/10.4014/jmb.1810.10009
  4. Simultaneous purification and depolymerization of Streptococcus pneumoniae serotype 2 capsular polysaccharides by trifluoroacetic acid vol.261, pp.None, 2011, https://doi.org/10.1016/j.carbpol.2021.117859